MA24604A1 - Compositions nouvelles d'inhibiteur selectif de reabsorption de serotonine et d'un b-bloquant - Google Patents

Compositions nouvelles d'inhibiteur selectif de reabsorption de serotonine et d'un b-bloquant

Info

Publication number
MA24604A1
MA24604A1 MA25165A MA25165A MA24604A1 MA 24604 A1 MA24604 A1 MA 24604A1 MA 25165 A MA25165 A MA 25165A MA 25165 A MA25165 A MA 25165A MA 24604 A1 MA24604 A1 MA 24604A1
Authority
MA
Morocco
Prior art keywords
blocker
novel compositions
selective serotonin
reabsorption inhibitor
serotonin reabsorption
Prior art date
Application number
MA25165A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA24604A1 publication Critical patent/MA24604A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25165A 1997-07-11 1998-07-10 Compositions nouvelles d'inhibiteur selectif de reabsorption de serotonine et d'un b-bloquant MA24604A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition

Publications (1)

Publication Number Publication Date
MA24604A1 true MA24604A1 (fr) 1999-04-01

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25165A MA24604A1 (fr) 1997-07-11 1998-07-10 Compositions nouvelles d'inhibiteur selectif de reabsorption de serotonine et d'un b-bloquant

Country Status (26)

Country Link
EP (1) EP0996466A2 (fr)
JP (1) JP2002508003A (fr)
KR (1) KR20010021644A (fr)
CN (1) CN1262627A (fr)
AP (1) AP2000001728A0 (fr)
AR (1) AR016128A1 (fr)
AU (1) AU9340198A (fr)
BG (1) BG104119A (fr)
BR (1) BR9810996A (fr)
CA (1) CA2295822A1 (fr)
CO (1) CO4950552A1 (fr)
DZ (1) DZ2556A1 (fr)
EA (1) EA200000112A1 (fr)
GB (1) GB9714675D0 (fr)
HU (1) HUP0003074A3 (fr)
ID (1) ID24191A (fr)
IL (1) IL133869A0 (fr)
MA (1) MA24604A1 (fr)
NO (1) NO20000107L (fr)
OA (1) OA11276A (fr)
PE (1) PE99699A1 (fr)
PL (1) PL338017A1 (fr)
SK (1) SK72000A3 (fr)
TR (1) TR200000074T2 (fr)
WO (1) WO1999002142A2 (fr)
ZA (1) ZA986138B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (fr) 1998-10-15 2010-02-10 Imperial Innovations Limited Compositions pour traiter la perte de poids
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
AU2005283829A1 (en) * 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) * 2006-09-08 2009-03-18 山东益康药业有限公司 复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (de) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
EP0792649A1 (fr) * 1996-02-29 1997-09-03 Eli Lilly And Company Traitement de l'insomnie

Also Published As

Publication number Publication date
NO20000107D0 (no) 2000-01-10
AU9340198A (en) 1999-02-08
ZA986138B (en) 2000-01-10
ID24191A (id) 2000-07-13
AR016128A1 (es) 2001-06-20
EP0996466A2 (fr) 2000-05-03
BG104119A (en) 2000-12-29
WO1999002142A3 (fr) 1999-04-15
PL338017A1 (en) 2000-09-25
HUP0003074A2 (hu) 2001-01-29
KR20010021644A (ko) 2001-03-15
WO1999002142A2 (fr) 1999-01-21
AP2000001728A0 (en) 2000-03-31
NO20000107L (no) 2000-01-10
CN1262627A (zh) 2000-08-09
OA11276A (en) 2003-07-31
BR9810996A (pt) 2000-08-08
TR200000074T2 (tr) 2000-05-22
IL133869A0 (en) 2001-04-30
PE99699A1 (es) 1999-12-21
CO4950552A1 (es) 2000-09-01
DZ2556A1 (fr) 2003-02-15
CA2295822A1 (fr) 1999-01-21
JP2002508003A (ja) 2002-03-12
HUP0003074A3 (en) 2001-12-28
EA200000112A1 (ru) 2000-10-30
GB9714675D0 (en) 1997-09-17
SK72000A3 (en) 2000-12-11

Similar Documents

Publication Publication Date Title
EE200000365A (et) Bispidiini uued arütmiavastased ühendid
ID24458A (id) Modifikasi rheologi in-sito poliolefin
PL339617A1 (en) Novel antagonists of neuropeptide y
DE69310957D1 (de) Organosiliconzusammensetzungen
PT1014987E (pt) Composicoes orais de levosimendano
DE69841796D1 (de) Gasmischung von konstanter Zusammensetzung
NO20002279D0 (no) Sammensetninger av lipidsenkende midler
MA24626A1 (fr) Compositions parenterales d'alatrofloxacine
MA24604A1 (fr) Compositions nouvelles d'inhibiteur selectif de reabsorption de serotonine et d'un b-bloquant
IT244003Y1 (it) Tenuta d'albero
DE69502429D1 (de) Auflösung von Gas
FI991343A (fi) Dihydropolyprenolien öljykoostumus
UA1629S (uk) Набір фестонів "веснянка-5"
UA1499S (uk) Набір етикеток "гусарська"
UA1498S (uk) Набір етикеток "сумська горобинова"
UA1497S (uk) Набір етекеток "ярославна"
UA1496S (uk) Набір етикеток "зубровка"
UA1478S (uk) Набір знаків розрізнення
UA1693S (uk) Набір етикеток "суми"
UA2501S (uk) Набір етикеток "кутузов"
UA2100S (uk) Комплект етикеток "хортиця"
UA2918S (uk) Комплект етикеток "славутич"
UA2400S (uk) Набір етикеток "ужгород"
UA2269S (uk) Комплект етикеток "миротворча"
BR7300677U (pt) Jogo fórmula-1